MDS & Myeloproliferative Neoplasms

MDS & Myeloproliferative Neoplasms

A collection of features and news articles published in ASH Clinical News related to myelodysplastic syndromes and myeloproliferative neoplasms.

Myeloid Malignancies: The Next Frontier for Immunotherapy

Building on the success of chimeric antigen receptor (CAR) T-cell therapies in lymphocytic leukemia and certain lymphomas – and the advances seen with checkpoint...

Standardized MRD Assay for FLT3-ITD-Mutated AML Could Guide AML Therapy Decisions

In a report published in Blood Advances, researchers describe a standardized minimal residual disease (MRD) assay that can detect FLT3-ITD mutations in patients with...

Final Results From PERSIST-2: Pacritinib Superior to Best Available Therapy in Patients With Myelofibrosis...

The development of the JAK2/FLT3 inhibitor pacritinib has been marked by ups and downs. In the phase III PERSIST-1 and PERSIST-2 trials, the drug...

The Genetic Signatures of AML Vary Between Younger and Older Patients

Acute myeloid leukemia (AML) is a collection of molecularly diverse diseases with similar phenotypes, and the distribution of these diseases differs between children and...

Mixed Results From SIMPLIFY-1 Complicate Myelofibrosis Treatment Decisions

The Janus kinase (JAK) inhibitor ruxolitinib is the only U.S. Food and Drug Administration–approved therapy for myelofibrosis (MF), but the resultant hematologic adverse events...

Eltrombopag Reduces Thrombocytopenic Events in Patients With AML and MDS, But Not as Much...

Compared with placebo, the oral thrombopoietic receptor agonist eltrombopag significantly lowered the incidence of thrombocytopenic events in patients with acute myeloid leukemia (AML) or...

Investigating a WT1 Peptide Vaccine in Patients With Acute Myeloid Leukemia

In an open-label, phase II study, treatment with galinpepimut-S (GPS) – a vaccine targeting the Wilms tumor 1 (WT1) protein – was well tolerated...

Teaching Old Drugs New Tricks?

When the U.S. Food and Drug Administration (FDA) approved CPX-351 (a fixed combination of daunorubicin and cytarabine), it appeared that everything old was new...

Newly Approved Drugs for AML: How to Use Them in Practice

In 2017, the U.S. Food and Drug Administration (FDA) approved several therapies for the treatment of hematologic malignancies, including four for acute myeloid leukemia...

Preliminary Results Show Flotetuzumab Well-Tolerated and Effective in Relapsed/Refractory AML and MDS

In early results from a phase I trial presented at the 2017 ASH Annual Meeting, researchers reported that the bispecific antibody flotetuzumab demonstrated anti-leukemic...
Advertisement

Current Issue

December 2019, Volume 5, Issue 15

This issue examines the hidden costs of participating in clinical trials, explores the pediatric hematology/oncology workforce, and more.